DOCSLIB.ORG

United States Patent (19) 11 Patent Number: 6,060,642 Tecott Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
United States Patent (19) 11 Patent Number: 6,060,642 Tecott Et Al US006060642A United States Patent (19) 11 Patent Number: 6,060,642 Tecott et al. (45) Date of Patent: May 9, 2000 54 SEROTONIN 5-HT6 RECEPTOR KNOCKOUT Roth, Bryan L., et al., “Binding of Typical and Atypical MOUSE Antipsychotic Agents 5-Hydroxytryptamine-6 and 5-Hydroxytryptamine–7 Receptors'." The Journal Of Phar 75 Inventors: Laurence H. Tecott, San Francisco; macology and Experimental Therapeutics (1994) vol. 268, Thomas J. Brennan, San Carlos, both No. (3):1403–1410. of Calif. Ruat, Martial, et al., “A Novel Rat Serotonin (5-HT) 73 Assignee: The Regents of the University of Receptor: Molecular Cloning, Localization And Stimulation Of cAMP Accumulation,” Biochemical and Biophysical California, Oakland, Calif. Communications Research Communications (May 28, 1993) 21 Appl. No.: 09/132,388 vol. 193, No. (1):268–276. Saudou, Frédéric, et al., “5-Hydroxytryptamine Receptor 22 Filed: Aug. 11, 1998 Subtypes. In Vertebrates And Inverterbrates,” Neurochem Int. (1994) vol. 25, No. (6):503–532. Related U.S. Application Data Sleight, A.J., et al., “Effects of Altered 5-HT Expression. In 60 Provisional application No. 60/055.817, Aug. 15, 1997. The Rat: Functional Studies Using Antisense Oligonucle 51 Int. Cl." ............................. C12N 5700; C12N 15/12; otides,” Behavioural Brain Research (1996) vol. AO1K 67/027; G01N 33/15; CO7H 21/04 73:245-248. 52 U.S. Cl. ................................... 800/3; 800/18; 800/21; Tecott, Laurence H., et al., “Behavioral Genetics: Genes And 800/9; 435/172.1; 435/1723; 435/325; Aggressiveness,” Current Biology (1996) vol. 6, No. 435/455; 536/23.5 (3):238–240. 58 Field of Search .................................... 800/3, 18, 21, Ward, Raymond P., et al., “Colocalization of Serotonin 800/9; 435/455, 172.1, 172.3, 325; 536/23.5 Receptor Subtypes 5-HT2A, 5-HT2C, and 5-HT6 With 56) References Cited Neuropeptides In Rat Striatum.” The Journal Of Compara tive Neurology (1996) vol. 370:405-414. U.S. PATENT DOCUMENTS Bradley et al., Bio/Technology, 10:534–539, 1992. 5,698,766 12/1997 Julius et al. ................................ 800/2 Saudou et al., Science, 265:1875-1878, 1994. OTHER PUBLICATIONS Kohen et al., GenBank Accession #L41146, 1996. Boss, F.G., et al., “Functional and Radioligand Binding Kohen et al., GenBank Accession #L41147, 1996. Characterization of Rat 5-HT Receptors Stably Expressed in HEK293 Cells,” Neuropharmacology (1997) vol. 36, No. Primary Examiner Deborah Crouch (4/5):713–720. ASSistant Examiner-Janet M. Kerr BourSon, Anne, et al., “Determination of the Role of the 5-HT Receptor in the Rat Brain: A Study Using Antisense Attorney, Agent, or Firm-Pamela J. Sherwood; Paula A. Oligonucleotides'.” The Journal of Pharmacology and Borden; Bozicevic, Field & Francis, LLP Experimental Therapeutics (1995) vol. 274, No. 57 ABSTRACT (1):173–180. Brennan, Thomas J., et al., “Sound-Induced Seizures. In The present invention features transgenic mice models for Serotonin 5-HT, Receptor Mutant Mice,” Nature Genetics gene function, wherein the transgenic mice are characterized (Aug. 1997) vol. 16:387–390. by having altered Serotonin 5-HT6 receptor gene function. Kohen, Ruth, et al., “Cloning, Characterization, and Chro The transgenic mice may be either homozygous or heterozy mosomal Localization of A Human 5-HT Serotonin Recep gous for a disruption in the endogenous 5-HT6 gene. Trans tor,” Journal of Neurochemistry (1996) vol. 66, No. genic mice homozygous for a disruption in the endogenous (1):47–56. 5-HT6 gene display a phenotype of increased anxiety behav Pierce, P.A., et al., “5-Hydroxytryptamine Receptor Sub ior including diminished investigation of foreign objects and type Messenger RNAS. In Rat Peripheral Sensory And Sym an elevation in Stretched attend postures. pathetic Ganglia: A Polymerase Chain Reaction Study,” Neuroscience (1996) vol. 70, No. (2):553–559. 3 Claims, 1 Drawing Sheet 6,060,642 1 2 SEROTONIN 5-HT6 RECEPTOR KNOCKOUT published rat Sequence contained a frame shift error. The MOUSE gene for the receptor maps to the human chromosome region 1p35-p36. Molecular cloning of the rat receptor is described This application claims the benefit of U.S. Provisional in Ruat et al. (1993) Biochem BiophyS Res Commun Application Ser. No. 60/055,817, filed Aug. 15, 1997. 193:268-276. This invention was made with Government support Boess et al. (1997) Neuropharmacology 36:713-720, under Grant no. DAO0282, awarded by the National Insti stably expressed the rat 5-HT6 receptor in HEK293 cells and tutes of Health. The Government has certain rights in this compared the affinity of a range of compounds in competi invention. tion binding experiments. The observed binding was LSD > omega-N-methyl-5-HT = bufote nine = 5 INTRODUCTION methoxy tryptamine > 5-HT22-methyl-5-HT =5- Background ben Zyl oxy trypt a mine = trypt a mine > 5 carboxamidotryptamined>5-HTQ. Receptor antagnosists The biogenic amine Serotonin (5-hydroxytryptamine; include methiothepin, clozapine, mianserin and ritanserin. 5-HT) is a brain neurotransmitter that has been strongly 15 The binding of typical and atypical antipsychotic agents to implicated in the pathophysiology and treatment of a wide 5-HT6 and 5-HT7 receptors is discussed in Roth et al. variety of neuropsychiatric disorders. It exerts its effects (1994) J Pharmacol Exp Ther 268: 1403–1410. Clozapine through a diverse family of Serotonin receptor Subtypes. Of and several related atypical antipsychotic agents (rilapine, the 14 different mammalian Serotonin receptors to have been olanzepine, tioSpirone, fluperlapine, clorotepine and cloned, all but one are members of the G-protein coupled Zotepine) had high affinities for 5-HT6 receptor. Several receptor Superfamily. Several of these, including the Sero dopamine-Selective antipsychotic agents (raclopride, rimca tonin 5-HT6 receptor, stimulate adenylyl cyclase via G zole and penfluridol) had essentially no affinity for either the coupling. 5-HT6 has a high affinity for several therapeuti 5-HT6 or 5-HT7 receptors. cally important antidepressant, antianxiety, hallucinogenic Ward and Dorsa (1996) J Comp Neurol 370:405-414 and antipsychotic drugs, particularly the atypical antipsy 25 describe the striatal distribution of the mRNAS of the chotics such as clozapine. The relevance of the 5-HT6 serotonin2A (5-HT2A), serotonin2C (5-HT2C), and seroto receptor to psychotherapeutics is indicated both through its niné (5-HT6) receptors in relation to enkephalin, Substance unique anatomical distribution and pharmacological prop P, and dynorphin expressing output neurons. Pierce et al. erties. (1996) Neuroscience 70:553–559 assayed for the presence Messenger RNA encoding the 5-HT6 receptor has been of messenger RNA for rat Serotonin receptor Subtypes in localized by in situ hybridization histochemistry to brain peripheral Sensory and Sympathetic ganglia was detected regions that regulate emotional responses, cognition and using the method of polymerase chain reaction. The pres motor function. This distribution pattern is generally ence of messenger RNA for 5-HT6 receptor was found matched by the localization of the 5-HT6 receptor protein within Superior cervical ganglia, but not lumbar Sympathetic identified by specific antibodies. This distribution is consis 35 ganglia. tent with the binding of psychoactive drugs. Therefore, The effects of administering 5-HT6 antisense oligonucle 5-HT6 receptors are implicated in the etiology of major otides to the rat brain are described in Sleight et al. (1996) psychiatric disorders and in the actions of psychiatric drugs. Behav Brain Res 73:245–248; and Bourson et al. (1995) J Antipsychotic medications are the treatment of choice for Pharmacol Exp Ther 274:173–180. A behavioral syndrome Schizoaffective disorders. Evidence to date Suggests that all 40 of yawning, Stretching and chewing was observed in treated of the antipsychotic drugs (except clozapine) are similarly ratS. effective in treating psychoses, with the differences being in milligram potency and Side effects. Sometimes patients view SUMMARY OF THE INVENTION the Side-effects of the antipsychotic drugs as being worse than their original psychosis. These include acute dystonic 45 Non-human transgenic animal models are provided for reactions, akathisia, Parkinsonism, in which akinesia is a serotonin 5-HT6 receptor (5-HT6) function, where the trans key feature, and tardive dyskinesia. Clozapine (Clozaril) has genic animal is characterized by having an altered 5-HT6 been proven to be more effective than all other antipsychotic gene. Alterations to the gene include deletions or other loSS drugs in treating certain disorders. It has reduced movement of function mutations, introduction of an exogenous gene Side-effects, but other Serious Side-effects limit its use. In 50 having a nucleotide Sequence with targeted or random mutations, introduction of an exogenous gene from another rare cases coma and death may result from the drug treat Species, or a combination thereof. The transgenic animals ment. may be either homozygous or heterozygous for the alter The importance of psychoactive drugs in present treat ation. The animals and cells derived therefrom are useful for ment of mental illness, and the presence of Serious and Screening biologically active agents that may modulate undesirable Side-effects with their use, makes the develop 55 ment of improved drugs of great interest. Animal models 5-HT6 receptor function. The screening methods are of useful in Screening assays provide a benefit by determining particular use for determining the Specificity and action of candidate agents that have improved specificity of action. antianxiety, antidepressant or antipsychotic drugs, particu Relevant Literature larly Serotoninergic drugs, or drugs that may interact with An Overview of 5-hydroxytryptamine receptor Subtypes 60 Serotonin receptors. The animals are useful as a model to in vertebrates and invertebrates may be found in Saudou and investigate the role of serotonin 5-HT6 receptors in normal Hen (1994) Neurochem Int 25:503–532. The cloning, brain function. characterization, and chromosomal localization of a human BRIEF DESCRIPTION OF THE DRAWINGS 5-HT6 serotonin receptor is described in Kohen et al. (1996) J Neurochem 66:47-56.
Load more

Recommended publications
  • 2D6 Substrates 2D6 Inhibitors 2D6 Inducers
    Physician Guidelines: Drugs Metabolized by Cytochrome P450’s 1 2D6 Substrates Acetaminophen Captopril Dextroamphetamine Fluphenazine Methoxyphenamine Paroxetine Tacrine Ajmaline Carteolol Dextromethorphan Fluvoxamine Metoclopramide Perhexiline Tamoxifen Alprenolol Carvedilol Diazinon Galantamine Metoprolol Perphenazine Tamsulosin Amiflamine Cevimeline Dihydrocodeine Guanoxan Mexiletine Phenacetin Thioridazine Amitriptyline Chloropromazine Diltiazem Haloperidol Mianserin Phenformin Timolol Amphetamine Chlorpheniramine Diprafenone Hydrocodone Minaprine Procainamide Tolterodine Amprenavir Chlorpyrifos Dolasetron Ibogaine Mirtazapine Promethazine Tradodone Aprindine Cinnarizine Donepezil Iloperidone Nefazodone Propafenone Tramadol Aripiprazole Citalopram Doxepin Imipramine Nifedipine Propranolol Trimipramine Atomoxetine Clomipramine Encainide Indoramin Nisoldipine Quanoxan Tropisetron Benztropine Clozapine Ethylmorphine Lidocaine Norcodeine Quetiapine Venlafaxine Bisoprolol Codeine Ezlopitant Loratidine Nortriptyline Ranitidine Verapamil Brofaramine Debrisoquine Flecainide Maprotline olanzapine Remoxipride Zotepine Bufuralol Delavirdine Flunarizine Mequitazine Ondansetron Risperidone Zuclopenthixol Bunitrolol Desipramine Fluoxetine Methadone Oxycodone Sertraline Butylamphetamine Dexfenfluramine Fluperlapine Methamphetamine Parathion Sparteine 2D6 Inhibitors Ajmaline Chlorpromazine Diphenhydramine Indinavir Mibefradil Pimozide Terfenadine Amiodarone Cimetidine Doxorubicin Lasoprazole Moclobemide Quinidine Thioridazine Amitriptyline Cisapride
    [Show full text]
  • Mechanisms of Action of Antipsychotic Drugs Of
    302 Current Neuropharmacology, 2009, 7, 302-314 Mechanisms of Action of Antipsychotic Drugs of Different Classes, Refractoriness to Therapeutic Effects of Classical Neuroleptics, and Individual Variation in Sensitivity to their Actions: PART I R. Miller* Otago Centre for Theoretical Studies in Psychiatry and Neuroscience (OCTSPAN), Department of Anatomy and Struc- tural Biology, School of Medical Sciences, University of Otago, P.O.Box 913, Dunedin, New Zealand Abstract: Many issues remain unresolved about antipsychotic drugs. Their therapeutic potency scales with affinity for dopamine D2 receptors, but there are indications that they act indirectly, with dopamine D1 receptors (and others) as pos- sible ultimate targets. Classical neuroleptic drugs disinhibit striatal cholinergic interneurones and increase acetyl choline release. Their effects may then depend on stimulation of muscarinic receptors on principle striatal neurones (M4 recep- tors, with reduction of cAMP formation, for therapeutic effects; M1 receptors for motor side effects). Many psychotic pa- tients do not benefit from neuroleptic drugs, or develop resistance to them during prolonged treatment, but respond well to clozapine. For patients who do respond, there is a wide (>ten-fold) range in optimal doses. Refractoriness or low sensitiv- ity to antipsychotic effects (and other pathologies) could then arise from low density of cholinergic interneurones. Clozap- ine probably owes its special actions to direct stimulation of M4 receptors, a mechanism available when indirect action is lost. Key Words: Antipsychotic drugs, neuroleptic drugs, cholinergic interneurones, D1 receptors, D2 receptors, muscarinic M1 receptors, muscarinic M4 receptors, neuroleptic threshold, atypical antipsychotic agents. 1. INTRODUCTION these drugs. Guidelines for dosage, and dose equivalences between different drugs have been based on group averages The first antipsychotic drug - chlorpromazine - was dis- derived from dose-finding trials.
    [Show full text]
  • A Drug Repositioning Approach Identifies Tricyclic Antidepressants As Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors
    Published OnlineFirst September 26, 2013; DOI: 10.1158/2159-8290.CD-13-0183 RESEARCH ARTICLE A Drug Repositioning Approach Identifi es Tricyclic Antidepressants as Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors Nadine S. Jahchan 1 , 2 , Joel T. Dudley 1 , Pawel K. Mazur 1 , 2 , Natasha Flores 1 , 2 , Dian Yang 1 , 2 , Alec Palmerton 1 , 2 , Anne-Flore Zmoos 1 , 2 , Dedeepya Vaka 1 , 2 , Kim Q.T. Tran 1 , 2 , Margaret Zhou 1 , 2 , Karolina Krasinska 3 , Jonathan W. Riess 4 , Joel W. Neal 5 , Purvesh Khatri 1 , 2 , Kwon S. Park 1 , 2 , Atul J. Butte 1 , 2 , and Julien Sage 1 , 2 Downloaded from cancerdiscovery.aacrjournals.org on September 29, 2021. © 2013 American Association for Cancer Research. Published OnlineFirst September 26, 2013; DOI: 10.1158/2159-8290.CD-13-0183 ABSTRACT Small cell lung cancer (SCLC) is an aggressive neuroendocrine subtype of lung cancer with high mortality. We used a systematic drug repositioning bioinformat- ics approach querying a large compendium of gene expression profi les to identify candidate U.S. Food and Drug Administration (FDA)–approved drugs to treat SCLC. We found that tricyclic antidepressants and related molecules potently induce apoptosis in both chemonaïve and chemoresistant SCLC cells in culture, in mouse and human SCLC tumors transplanted into immunocompromised mice, and in endog- enous tumors from a mouse model for human SCLC. The candidate drugs activate stress pathways and induce cell death in SCLC cells, at least in part by disrupting autocrine survival signals involving neurotransmitters and their G protein–coupled receptors. The candidate drugs inhibit the growth of other neuroendocrine tumors, including pancreatic neuroendocrine tumors and Merkel cell carcinoma.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Achat Viagra Puissant ### Ablation Prostate Et Viagra >>> Kvadridze.Github.Io
    Viagra est indiquée pour le traitement de la dysfonction érectile masculine. >>> ORDER NOW <<< Achat viagra puissant Tags: ordonnance de viagra combien de temps dur viagra comment peut on se procurer du viagra efficacité viagra générique un site fiable pour acheter du viagra le viagra sur ordonnance danger dacheter du viagra sur internet prix cachet viagra combien coute le viagra au maroc le rôle de viagra peut acheter du viagra sans ordonnance quesque cest viagra composition de viagra acheter viagra paris sans ordonnance comment se procurer viagra sans ordonnance comment reconnaitre le faux viagra quand faut il prendre viagra comment acheter du viagra au quebec lancement du viagra quest ce que cest le viagra viagra pfizer mode demploi les conséquences du viagra edex plus viagra comment prendre de viagra forum viagra pas cher commande de viagra en ligne meme effet que viagra prendre la moitié dun viagra experience viagra femme A vaginal ring can slip out of the vagina. In the event of overdosage, general symptomatic and achat viagra puissant measures are indicated as required Resistance to azithromycin may be inherent or acquired. Comments: Take one pill a day. Ca 20 minuter senare börjar mina kollegor droppa in i ordningen: Susanne, Britt, Emma, Nina, Gunnel, Eva och sist Barbro. Epidemiologic investigations of this outbreak demonstrated that individuals in close contact with the index case or with exposure to poultry were at risk of being infected. 25 mg pour femme viagra cherche 2 weeks or until I "felt" like I could go lower. It might take a while to adapt to it, since it will lower your blood pressure.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Visit Web Page
    Viagra est indiquée pour le traitement de la dysfonction érectile masculine. >>> ORDER NOW <<< Combien de comprimes dans une boite de viagra Tags: préservatif effet viagra viagra sans ordonnance belgique combien coute du viagra acheter vrai viagra sur internet levitra meilleur que viagra achat generique viagra saisie de viagra acheter du viagra au luxembourg commande viagra en ligne suisse durée de validité dune ordonnance viagra prescription médicale pour viagra depuis quand existe le viagra les effet secondaire de viagra générique viagra belgique duree efficacite du viagra site viagra sans ordonnance quesqui peut remplacer le viagra le plus efficace cialis ou viagra quel est le plus efficace cialis ou viagra durée effet viagra 100 combien de temps dure l effet viagra meilleur viagra pour homme pays vente libre viagra cest quoi sildenafil ou acheter du viagra a lyon je veux prendre du viagra prix du viagra pour femme asenapine, clorotepine, clozapine, fluperlapine, iloperidone, melperone, olanzapine, paliperidone, quetiapine, risperidone, sertindole, ziprasidone, zotepine) Tetracyclic antidepressants (e. Diet dans une boite are any types of pharmacological agents marketed to control or reduce weight. Then, with the tablet score facing you, apply pressure and snap the tablet segments apart (segments breaking incorrectly should not be used). The fundamental process that triggers synaptic transmission is the action https://kvadridze.github.io/saquxedozy/production-du-viagra.pdf, a propagating electrical signal that is generated by exploiting
    [Show full text]
  • DBL™ Promethazine Hydrochloride Injection BP
    DBL™ Promethazine Hydrochloride Injection BP 1. NAME OF THE MEDICINE Promethazine hydrochloride 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each mL of the solution contains 25.0 mg promethazine hydrochloride, 0.10 mg disodium edetate, 1.30 microlitre glacial acetic acid, 27.2 mg sodium acetate and 1.32 mg sodium metabisulfite in water for injections. Excipient(s) with known effect Sodium metabisulfite For the full list of excipients, see section 6.1 List of Excipients. 3. PHARMACEUTICAL FORM Solution for injection. DBL™ Promethazine Hydrochloride Injection BP is a clear, colourless solution of pH 5.0 to 6.0. 4. CLINICAL PARTICULARS 4.1 Therapeutic Indications DBL™ Promethazine Hydrochloride Injection BP is indicated for the following conditions: Treatment of allergic reactions such as: uncomplicated allergic conditions of the immediate type, e.g., pruritus, urticaria and angioedema, when oral therapy is impossible or contraindicated. Treatment and prevention of vomiting including: motion sickness; drug induced nausea; prevention and control of nausea and vomiting associated with certain types of anaesthesia and surgery, such as procedures with a high incidence of post-operative vomiting (e.g., gynaecological surgery, strabismus or middle ear surgery, and electroconvulsive therapy); in patients with a past history of motion sickness or post- operative vomiting; and in patients in whom avoidance of vomiting is crucial (e.g., neurosurgery and eye surgery). Page 1 of 10 Promethazine has sedative effects and it is also used in: pre-operative, post-operative and obstetric (during labour) sedation. 4.2 Dose and Method of Administration Dosage Allergic conditions Adults: 25 mg to 50 mg by deep intramuscular injection or slow intravenous injection; may be repeated within two hours if necessary.
    [Show full text]
  • Astrazenecateva09252009
    United States Court of Appeals for the Federal Circuit 2008-1480, -1481 ASTRAZENECA PHARMACEUTICALS LP and ASTRAZENECA UK LIMITED, Plaintiffs-Appellees, v. TEVA PHARMACEUTICALS USA, INC. and TEVA PHARMACEUTICAL INDUSTRIES, LTD., Defendants-Appellants, and SANDOZ, INC., Defendant-Appellant. Henry J. Renk, Fitzpatrick Cella, Harper & Scinto, of New York, New York, argued for plaintiffs-appellees. With him on the brief were Bruce C. Haas; Charles E. Lipsey, Finnegan, Henderson, Farabow Garrett & Dunner, LLP, of Reston, Virginia, and Thomas A. Stevens, AstraZeneca Pharmaceuticals LP, of Wilmington, Delaware. Ira J. Levy, Goodwin Proctor LLP, of New York, New York, argued for defendants- appellants Teva Pharmaceuticals USA, Inc., et al. With him on the brief were Henry C. Dinger, Daryl L. Wiesen and John T. Bennett, of Boston, Massachusetts. Douglass C. Hochstetler, Schiff Hardin LLP, of Chicago, Illinois, argued for defendant- appellant Sandoz, Inc. With him on the brief were Jason G. Harp; and Beth D. Jacob, of New York, New York. Appealed from: United States District Court for the District of New Jersey Judge Joel A. Pisano United States Court of Appeals for the Federal Circuit 2008-1480,-1481 ASTRAZENECA PHARMACEUTICALS LP and ASTRAZENECA UK LIMITED, Plaintiffs-Appellees, v. TEVA PHARMACEUTICALS USA, INC. and TEVA PHARMACEUTICAL INDUSTRIES, LTD., Defendants-Appellants, and SANDOZ, INC., Defendant-Appellant. Appeal from the United States District Court for the District of New Jersey in consolidated Case Nos. 05-CV-5333, 06-CV-1528, 07-CV-1632, and 07-CV-3001, Judge Joel A. Pisano. ___________________________ DECIDED: September 25, 2009 ___________________________ Before NEWMAN, RADER, and PROST Circuit Judges. NEWMAN, Circuit Judge.
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • The Wrap Is Right Reflux for 100
    Retching Post‐Fundoplication Miguel Saps, MD Associate Professor of Pediatrics Northwestern University, Feinberg School of Medicine Director of Motility and Functional Bowel Disorders Ann & Robert H. Lurie Children’s Hospital of Chicago The Wrap is Right Reflux For 100 Einstein died in 1955 of internal bleeding due to rupture of abdominal aortic aneurysm, surgically reinforced by Dr. Rudolph Nissen in 1948 at Brooklyn Jewish Hospital. Antireflux Surgery • “Gastric fundoplication”‐ among most common pediatric surgeries. Most common surgery GERD • Success‐ Fundoplication effective surgical treatment GERD • Beneficial‐ High level satisfaction. • >2/3 parents report improved GERD symptoms, feed tolerance, nutrition, chest infections 1 GERD: Transient LES relaxations, decreased LES tone, delay gastric emptying, prolonged postprandial relaxation ‐Fundoplication reduces frequency of TLESR, increases LES resting pressure 1‐ Permanently alters gastroesophageal anatomy and function 2‐ Type of patients • Neurologic dysfunction ‐ 40% fundoplication surgeries in children • GERD common in neurological dysfunction • GERD affect quality of life (symptomatic esophagitis, peptic stricture, recurrent pneumonia) • Complications: reflux esophagitis, recurrent pulmonary aspiration, dysphagia (malnutrition, recurrent pulmonary aspiration) • Poor coordination of swallowing‐ undernutrition and recurrent aspiration • GT feeding‐nutritional rehabilitation and/or risk of aspiration (GT may aggravate reflux and aspiration) • GER less responsive to medical therapy than in neurologically normal individuals. O'Loughlin EV, et al. J Pediatr Gastroenterol Nutr. 2013;56:46‐50 • Antireflux surgery‐ prevent GERD‐morbidity, reduce risk of aspiration, prevent severe GERD Neurological Status Major Predictor of Operative Success • Incidence of postoperatory complications greater than neurologically intact • X 4 more patients with neurological dysfunction reoperated (19% vs 5%) • Surgical‐ Wrap herniation due to crural disruption is the most common cause of operative failure.
    [Show full text]